Hyperimmunized Egg Antibodies for Coronavirus Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to treat and prevent coronavirus infections, particularly for SARS-CoV-2, as existing technologies are inadequate in effectively addressing the severity and spread of these infections.
Innovation Solution
A method involving the administration of a hyperimmunized egg product obtained from an egg-producing animal, which contains a therapeutically effective amount of antibodies specific to coronaviruses, including SARS-CoV-2, to prevent or treat coronavirus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunization methods are used to produce antibodies, then the immune response is limited by the host's natural immune capacity, but the antibody titer and effectiveness are insufficient for severe coronavirus infections
Solution Approach 1:
The egg-producing animal is hyperimmunized in advance with coronavirus antigens (such as spike protein, nucleocapsid protein, or whole virus) before egg collection, so that the animal's immune system produces high-titer antibodies that are then secreted into the eggs. This preliminary immunization action ensures that when eggs are collected and administered to infected subjects, they contain pre-formed high-concentration antibodies ready for immediate therapeutic effect.
Solution Approach 2:
The egg product serves as an intermediary vehicle to deliver high-titer antibodies from the hyperimmunized animal to the infected human subject. Instead of directly injecting antibodies from the animal's blood, the patent uses eggs as a natural bioreactor and delivery system, where antibodies are secreted into the egg yolk and can be administered orally or parenterally to treat coronavirus infection.
2Reliability
If hyperimmunized egg products are administered to prevent or treat coronavirus infection, then viral binding to ACE2 receptor and cellular entry are inhibited, but the complexity of producing and administering the treatment increases
Solution Approach 1:
The hyperimmunized egg product contains all necessary therapeutic components (high-titer antibodies against coronavirus antigens) in a self-contained form that can be administered relatively simply. The egg matrix itself protects the antibodies and facilitates their delivery to the subject, reducing the need for complex formulation and administration protocols while maintaining high protective efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of hyperimmunized egg products with high titers of antibodies effectively prevents or treats coronavirus infections by reducing the binding of the virus to the ACE2 receptor and inhibiting viral entry into cells.
Implementation Method 1
the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus
Implementation Method 2
The use of hyperimmunized egg products with high titers of antibodies effectively prevents or treats coronavirus infections by reducing the binding of the virus to the ACE2 receptor and inhibiting viral entry into cells
Data Source
AI summary
In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.